Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
The 50% PFSR-18 for CB was contained within the 80% CI for (42-64%). Therefore the null hypothesis could not be rejected. Accordingly this combination does not warrant further investigation. PFSR-18 was confirmed as a strong predictor of survival.
2815-2822
O'Brien, Mary E.R.
221cd79f-cd1c-4635-ad9f-31ff02c0edf6
Gaafar, Rabab M.
7934173f-d9ca-4aa9-bd02-1495d8634d2b
Popat, Sanjay
10c354ba-52df-4cc8-8f46-7994dc241a0a
Grossi, Francesco
3c0c392c-d6dc-440a-95ce-b92866bb08e1
Price, Allan
e1b2acdc-6cb5-4c30-9a48-00ae52cd0399
Talbot, Denis C.
a45616a0-661d-431f-8dd1-5457f8b9c16f
Cufer, Tanja
e7a3fbb7-1036-406a-a82b-448e99417373
Ottensmeier, Christian
42b8a398-baac-4843-a3d6-056225675797
Danson, Sarah
dc545bf0-6b2f-462d-93c2-9c9636fc3c44
Pallis, Athanasios
2669a4bb-2bd3-492c-b3cf-cc0d9e92a33b
Hasan, Baktiar
f824e166-8126-4ed7-945d-0e6184fbc783
Van Meerbeeck, Jan P.
61be7a9f-fdf7-49fd-ad24-a7cf92a58ffa
Baas, Paul
0728a501-5af7-44ef-8972-f185435bed5e
September 2013
O'Brien, Mary E.R.
221cd79f-cd1c-4635-ad9f-31ff02c0edf6
Gaafar, Rabab M.
7934173f-d9ca-4aa9-bd02-1495d8634d2b
Popat, Sanjay
10c354ba-52df-4cc8-8f46-7994dc241a0a
Grossi, Francesco
3c0c392c-d6dc-440a-95ce-b92866bb08e1
Price, Allan
e1b2acdc-6cb5-4c30-9a48-00ae52cd0399
Talbot, Denis C.
a45616a0-661d-431f-8dd1-5457f8b9c16f
Cufer, Tanja
e7a3fbb7-1036-406a-a82b-448e99417373
Ottensmeier, Christian
42b8a398-baac-4843-a3d6-056225675797
Danson, Sarah
dc545bf0-6b2f-462d-93c2-9c9636fc3c44
Pallis, Athanasios
2669a4bb-2bd3-492c-b3cf-cc0d9e92a33b
Hasan, Baktiar
f824e166-8126-4ed7-945d-0e6184fbc783
Van Meerbeeck, Jan P.
61be7a9f-fdf7-49fd-ad24-a7cf92a58ffa
Baas, Paul
0728a501-5af7-44ef-8972-f185435bed5e
O'Brien, Mary E.R., Gaafar, Rabab M., Popat, Sanjay, Grossi, Francesco, Price, Allan, Talbot, Denis C., Cufer, Tanja, Ottensmeier, Christian, Danson, Sarah, Pallis, Athanasios, Hasan, Baktiar, Van Meerbeeck, Jan P. and Baas, Paul
(2013)
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
European Journal of Cancer, 49 (13), .
(doi:10.1016/j.ejca.2013.05.008).
(PMID:23791541)
Abstract
The 50% PFSR-18 for CB was contained within the 80% CI for (42-64%). Therefore the null hypothesis could not be rejected. Accordingly this combination does not warrant further investigation. PFSR-18 was confirmed as a strong predictor of survival.
This record has no associated files available for download.
More information
e-pub ahead of print date: 20 June 2013
Published date: September 2013
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 396348
URI: http://eprints.soton.ac.uk/id/eprint/396348
ISSN: 0959-8049
PURE UUID: 3e3ee8d1-b0c4-469b-82bf-16677ce7e942
Catalogue record
Date deposited: 08 Jun 2016 15:25
Last modified: 15 Mar 2024 00:52
Export record
Altmetrics
Contributors
Author:
Mary E.R. O'Brien
Author:
Rabab M. Gaafar
Author:
Sanjay Popat
Author:
Francesco Grossi
Author:
Allan Price
Author:
Denis C. Talbot
Author:
Tanja Cufer
Author:
Sarah Danson
Author:
Athanasios Pallis
Author:
Baktiar Hasan
Author:
Jan P. Van Meerbeeck
Author:
Paul Baas
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics